Cellectar Biosciences Files 8-K on Financials
Ticker: CLRB · Form: 8-K · Filed: Mar 27, 2024 · CIK: 1279704
| Field | Detail |
|---|---|
| Company | Cellectar Biosciences, Inc. (CLRB) |
| Form Type | 8-K |
| Filed Date | Mar 27, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-K, company-update
TL;DR
Cellectar Biosciences dropped an 8-K detailing its financial condition and operations as of March 27, 2024.
AI Summary
Cellectar Biosciences, Inc. filed an 8-K on March 27, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company incorporated in Delaware and headquartered in Florham Park, NJ.
Why It Matters
This filing provides investors with an update on Cellectar Biosciences' financial performance and operational status, which is crucial for evaluating the company's health and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial reporting filing (8-K) and does not contain new material events or significant financial changes.
Key Players & Entities
- Cellectar Biosciences, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- Florham Park, NJ (location) — Principal executive offices
- NOVELOS THERAPEUTICS, INC. (company) — Former company name
- COMMON HORIZONS INC (company) — Former company name
FAQ
What is the primary purpose of this 8-K filing for Cellectar Biosciences?
The primary purpose of this 8-K filing is to report on Cellectar Biosciences, Inc.'s Results of Operations and Financial Condition, and to include Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on March 27, 2024.
Where are Cellectar Biosciences' principal executive offices located?
Cellectar Biosciences' principal executive offices are located at 100 Campus Drive, Florham Park, NJ, 07932.
What is Cellectar Biosciences' Standard Industrial Classification (SIC) code?
Cellectar Biosciences' Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Has Cellectar Biosciences undergone any previous name changes?
Yes, Cellectar Biosciences was formerly known as NOVELOS THERAPEUTICS, INC. (name change effective 20050617) and prior to that, COMMON HORIZONS INC (name change effective 20040211).
Filing Stats: 454 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-03-27 06:45:20
Key Financial Figures
- $0.00001 — ch registered Common Stock, par value $0.00001 per share CLRB The Nasdaq Capital M
Filing Documents
- tm249908d1_8k.htm (8-K) — 25KB
- tm249908d1_ex99-1.htm (EX-99.1) — 69KB
- 0001104659-24-039341.txt ( ) — 271KB
- clrb-20240327.xsd (EX-101.SCH) — 3KB
- clrb-20240327_lab.xml (EX-101.LAB) — 33KB
- clrb-20240327_pre.xml (EX-101.PRE) — 22KB
- tm249908d1_8k_htm.xml (XML) — 3KB
02. Results of Operations and Financial
Item 2.02. Results of Operations and Financial Condition. On March 27, 2024, we issued a press release announcing our financial results for the year ended December 31, 2023 and provided a corporate update. A copy of the press release is furnished as Exhibit 99.1 and is incorporated by reference herein.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits (d) Exhibits Number Title 99.1 Press release dated March 27, 2024, titled "Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update" 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CELLECTAR BIOSCIENCES, INC. Date: March 27, 2024 By: /s/ Chad J. Kolean Name: Chad J. Kolean Title: Chief Financial Officer